EX-VIVO PATIENT DERIVED XENOGRAFT STUDIES

PHENOVISTA HAS PARTNERED WITH CHAMPIONS ONCOLOGY TO PERFORM EX-VIVO STUDIES ON THEIR PATIENT DERIVED XENOGRAFT (PDX) MODELS. THE >1200 PDX MODELS REPRESENT A DIVERSE SET OF TUMOR TYPES WITH EXTENSIVE CLINICAL AND MOLECULAR CHARACTERIZATION. AT PHENOVISTA WE GENERATE 3D TUMOR FRAGMENTS FROM THE PDX TISSUE, FOR EVALUATION OF THERAPEUTIC TREATMENT CANDIDATES BY IMAGING.

  • RAPID IN VITRO ASSESSMENT OF DRUG TREATMENTS (SMALL MOLECULES, BIOLOGICS, IMMUNO-THERAPIES, COMBINATION STUDIES)

  • HIGHLY MULIPLEXED DETERMINATION OF CANDIDATE DRUGS AND DOSING FOR IN VIVO STUDIES

  • 3D CULTURES PROVIDE BETTER PREDICTIVITY OF DRUG RESISTANCE

Objective

Client was interested in evaluating chemotherapeutic agents, including standard of care and combinations, in ex vivo NSCLC PDX models

Design

PDX tumors were dissociated to establish 3D tumor fragments that can be cultured and tested in high throughput in vitro

Advantages

3D tumor fragments can be cultured in vitro and tested at high throughput in a physiologically relevant microenvironment

Tumor fragments can be assayed in multiplexed imaging assays for evaluation of drug sensitivity

Combined with the extensive molecular and clinical information on the donor, the data can yield new mechanistic insights

PDX STUDIES: SMALL MOLECULE TREATMENT

picpic
picpicpicpic
Scroll to Top